Carroll Financial Associates’s Maravai LifeSciences MRVI Stock Holding History

Carroll Financial Associates’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10	Closed	–	–	1821
2021 Q3	$0	Sell	10 -983	-99%	-$47.9K	﹤0.01%	1878
2021 Q2	$41K	Buy	+993	New	+$38.5K	﹤0.01%	869

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Carroll Financial Associates's MRVI Position: Q4 2021 in Review

Carroll Financial Associates sold out of Maravai LifeSciences (MRVI) in Q4 2021, closing a stake of 10 shares.

Carroll Financial Associates first reported a position in MRVI in Q2 2021 and held it in 2 quarters. The position peaked at $41K in Q2 2021. 229 funds tracked by Wall St. Rank hold MRVI as of Q4 2021.

Carroll Financial Associates reported no remaining Maravai LifeSciences position as of Q4 2021 after selling out during the quarter.
Carroll Financial Associates sold 10 Maravai LifeSciences shares in Q4 2021.
Carroll Financial Associates first reported a position in Maravai LifeSciences in Q2 2021 and held it in 2 quarters.
Carroll Financial Associates's Maravai LifeSciences position peaked at $41K in Q2 2021.
229 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.